TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32005308

Group type: EXPERIMENTAL
Intervention: High-dose aminoglycoside group (≥75 mg/kg/week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-existing hearing loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age (per 10 years)
Number of subjects: 0
Study: 35301596

Group type: EXPERIMENTAL
Intervention: Office bleaching
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Home bleaching
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control group for office bleaching
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control group for home bleaching
Number of subjects: 260
Study: 33565010

Group type: EXPERIMENTAL
Intervention: Laparoscopic low-pressure cholecystectomy (LPLC) at 8 mmHg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard pressure laparoscopic cholecystectomy (SPLC) at 12 mmHg
Number of subjects: 100
Study: 35929765

Group type: EXPERIMENTAL
Intervention: 5-mm laterally wedged insole
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ankle-foot orthosis
Number of subjects: 28
Study: 32286683

Group type: EXPERIMENTAL
Intervention: Brodalumab
Number of subjects: 442

Group type: COMPARATOR
Intervention: Brodalumab after placebo
Number of subjects: 442
Study: 33301738

Group type: EXPERIMENTAL
Intervention: Oral panobinostat 20 mg three times weekly
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Oral panobinostat 20 mg twice weekly
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Oral panobinostat 10 mg three times weekly
Number of subjects: 248
Study: 33031887

Group type: EXPERIMENTAL
Intervention: M->A (adhesive applied before matrix application)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: A->M (adhesive applied after matrix application)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CU + CV (Clearfil Universal Bond Quick with crystal violet dye)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CSE (Clearfil SE Bond2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CSE with CV addition
Number of subjects: 20
Study: 33507601

Group type: EXPERIMENTAL
Intervention: Attachment avoidance as a mediator
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Perceived relatedness
Number of subjects: 206
Study: 36207474

Group type: EXPERIMENTAL
Intervention: AI/ML-based CAD devices for detection of colorectal polyps
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standalone software testing for AI/ML-based CAD devices
Number of subjects: 45
Study: 34016665

Group type: EXPERIMENTAL
Intervention: UK official information (no mention of false negatives/positives)
Number of subjects: 1744

Group type: COMPARATOR
Intervention: Control group (no additional information)
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: New Zealand wording (highlighted uncertainties)
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: New Zealand wording
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: UK wording
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: Positive results
Number of subjects: 1744
Study: 32097286

Group type: EXPERIMENTAL
Intervention: Workplace program of moderate intensity exercises for 7 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home-based exercises illustrated in a booklet and video for 7 weeks
Number of subjects: 0
Study: 36268789

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg (maximum of 5 mg) of dexamethasone diluted to a total volume of 2 ml with 0.9% saline (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2 ml of 0.9% saline (n = 50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg (maximum of 5 mg) of dexamethasone
Number of subjects: 100
Study: 32951502

Group type: EXPERIMENTAL
Intervention: Swedish Renal Registry (SRR) data on vascular access
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: SRR registrations
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Registrations of central venous catheters (CVCs)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Registrations of placed fistulas in 2017
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Vascular access type initiating hemodialysis
Number of subjects: 120
Study: 33151802

Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate concentrate injections via superolateral, anteromedial or anterolateral portals
Number of subjects: 111
Study: 35987467

Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam plus metronidazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meropenem plus placebo
Number of subjects: 0
Study: 33548338

Group type: EXPERIMENTAL
Intervention: Chemoradiation therapy
Number of subjects: 442

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Baseline neutrophilia
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Elevated or increasing neutrophil count after induction chemotherapy
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Elevated or increasing neutrophil count
Number of subjects: 442
Study: 35616304

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory exercise
Number of subjects: 24
Study: 34688915

Group type: EXPERIMENTAL
Intervention: Identify, Coordinate, and Enhance (ICE) care model
Number of subjects: 2971

Group type: EXPERIMENTAL
Intervention: Individualized Postural Therapy (IPT)
Number of subjects: 2971

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2971
Study: 33558215

Group type: EXPERIMENTAL
Intervention: Axillary temperature measurement
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rectal temperature measurement
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rectal and axillary temperature measurements
Number of subjects: 72
Study: 33186338

Group type: EXPERIMENTAL
Intervention: Immediate antiretroviral therapy
Number of subjects: 207

Group type: COMPARATOR
Intervention: Deferred antiretroviral therapy
Number of subjects: 207
Study: 35331432

Group type: EXPERIMENTAL
Intervention: Vein of Marshall ethanol infusion (VOMEt) as first step preceding RF ablation (VOMFIRST group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Radiofrequency (RF) ablation as a first step preceding VOMEt (RFFIRST group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups after additional touch-up RF ablation
Number of subjects: 70
Study: 34781656

Group type: EXPERIMENTAL
Intervention: Subcutaneous Pegylated erythropoietin at a dose of 0.6 mcg/kg body weight, once every two weeks along with intravenous iron 100 mg/week for 3 months.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Subcutaneous darbepoetin alfa at a dose of 0.45 mcg/kg body weight once weekly along with intravenous iron 100 mg/week for 3 months.
Number of subjects: 40
Study: 34114138

Group type: EXPERIMENTAL
Intervention: Brinzolamide-brimonidine fixed combination (1 drop, instilled 2 hours before injection)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no prophylactic medication)
Number of subjects: 47
Study: 32853281

Group type: EXPERIMENTAL
Intervention: Auricular stimulation (AS)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Expressive writing (EW)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No intervention (NI)
Number of subjects: 37
Study: 32567474

Group type: EXPERIMENTAL
Intervention: SB fermented with Lactobacillus casei TH14, cellulase, and molasses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rice straw (RS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: SB
Number of subjects: 0
Study: 33690610

Group type: EXPERIMENTAL
Intervention: Pratt pouch model dispensing nevirapine prophylaxis
Number of subjects: 660

Group type: COMPARATOR
Intervention: Standard nevirapine syrup
Number of subjects: 660
Study: 35239204

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 5674

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5674
Study: 32501994

Group type: EXPERIMENTAL
Intervention: Combination therapy (heat-clearing and detoxifying Chinese medicines combined with conventional therapy)
Number of subjects: 947

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 947

Group type: EXPERIMENTAL
Intervention: Jinlianqingre effervescent tablets (part of combination therapy)
Number of subjects: 947

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 947
Study: 37079268

Group type: EXPERIMENTAL
Intervention: Active treatment group (App + usual care)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 197
Study: 36432446

Group type: EXPERIMENTAL
Intervention: Smartphone app and smart band (Mi Band 2, Xiaomi) for 3 months
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 253
Study: 32346959

Group type: EXPERIMENTAL
Intervention: TAZ/BM cream
Number of subjects: 600

Group type: COMPARATOR
Intervention: TAZ gel
Number of subjects: 600

Group type: COMPARATOR
Intervention: BM cream
Number of subjects: 600
Study: 35092347

Group type: EXPERIMENTAL
Intervention: Amlodipine and chelation therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Chelation therapy only
Number of subjects: 64
Study: 34919248

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution (LRS)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Normal Saline solution (NSS)
Number of subjects: 142
Study: 35979636

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 703

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT) with ticagrelor plus aspirin
Number of subjects: 703
Study: 33517104

Group type: EXPERIMENTAL
Intervention: Manipulation plus exercise
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Myofascial release plus exercise
Number of subjects: 45

Group type: COMPARATOR
Intervention: Exercise only (control)
Number of subjects: 45
Study: 34103538

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3649

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3649
Study: 32247530

Group type: EXPERIMENTAL
Intervention: Mindfulness and self-care program consisting of 9 weekly sessions of 90min, daily practice, and reinforcement sessions at 1 month, 3, 6, and 12 months.
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Mindfulness and self-care program
Number of subjects: 314
Study: 35871140

Group type: EXPERIMENTAL
Intervention: Care coordination
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 81
Study: 34519769

Group type: EXPERIMENTAL
Intervention: Multicomponent hypertension management program
Number of subjects: 1432

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1432
Study: 33985501

Group type: EXPERIMENTAL
Intervention: Hydrogen/oxygen mixture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxygen therapy
Number of subjects: 100
Study: 36378660

Group type: EXPERIMENTAL
Intervention: Adherence clubs (ACs)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Primary health care (PHC) ART clinics
Number of subjects: 220
Study: 32546199

Group type: EXPERIMENTAL
Intervention: Rabies vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34418414

Group type: EXPERIMENTAL
Intervention: Incremental hemodialysis (twice‐weekly sessions, upwardly adjusting hemodialysis dose)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard hemodialysis (thrice weekly for 3.5‐4 hours, minimum Dialysis Std Kt/V of 2)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Incremental hemodialysis
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard hemodialysis
Number of subjects: 55
Study: 32955013

Group type: EXPERIMENTAL
Intervention: Decide2Rest
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control
Number of subjects: 73
Study: 32658349

Group type: EXPERIMENTAL
Intervention: Participation in the ASPiVLU trial
Number of subjects: 31
Study: 34596225

Group type: EXPERIMENTAL
Intervention: Probiotic preparation (Canada: Lactobacillus rhamnosus R0011/Lactobacillus helveticus R0052; US: L. rhamnosus GG)
Number of subjects: 1565

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1565

Group type: EXPERIMENTAL
Intervention: L. rhamnosus R0011/L. helveticus R0052 (among adenovirus-infected children)
Number of subjects: 1565

Group type: EXPERIMENTAL
Intervention: Adenovirus
Number of subjects: 1565

Group type: EXPERIMENTAL
Intervention: Norovirus
Number of subjects: 1565

Group type: EXPERIMENTAL
Intervention: Rotavirus
Number of subjects: 1565

Group type: EXPERIMENTAL
Intervention: Bacteria
Number of subjects: 1565
Study: 34214889

Group type: EXPERIMENTAL
Intervention: Detection of Theileria spp. (50.5%)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Detection of Theileria parva (27.9%)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Detection of Anaplasma marginale (19.2%)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Detection of Anaplasma platys‐like (11.5%)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Detection of Babesia bigemina (8.7%)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis of T. parva p104 gene
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Sequencing of Theileria spp. 18S rRNA gene
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Risk factors associated with TBPs
Number of subjects: 208
Study: 33801621

Group type: EXPERIMENTAL
Intervention: Flywheel Resistance Training (FRT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional Strength Training (TST)
Number of subjects: 30
Study: 33297761

Group type: EXPERIMENTAL
Intervention: 18F‐fluoride uptake
Number of subjects: 183
Study: 35072215

Group type: EXPERIMENTAL
Intervention: NMES with pulse width of 300 μs
Number of subjects: 46

Group type: COMPARATOR
Intervention: NMES with pulse width of 200 μs
Number of subjects: 46
Study: 33570309

Group type: EXPERIMENTAL
Intervention: Flipped classroom
Number of subjects: 493

Group type: COMPARATOR
Intervention: Traditional auditorium lectures
Number of subjects: 493
Study: 35149233

Group type: EXPERIMENTAL
Intervention: Trofinetide (200 mg/kg twice daily)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Trofinetide (50, 100, and 200 mg/kg BID)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Trofinetide
Number of subjects: 187
Study: 33785707

Group type: EXPERIMENTAL
Intervention: Bean-based diet
Number of subjects: 63

Group type: COMPARATOR
Intervention: White rice control
Number of subjects: 63
Study: 35705139

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg orally per day for 12 weeks)
Number of subjects: 0
Study: 33888362

Group type: EXPERIMENTAL
Intervention: Animated virtual healthcare assistant
Number of subjects: 1363

Group type: COMPARATOR
Intervention: Static virtual healthcare assistant
Number of subjects: 1363

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 1363
Study: 36332442

Group type: EXPERIMENTAL
Intervention: Virtual reality intervention for dementia care education
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study: 35870380

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 28
Study: 33839523

Group type: EXPERIMENTAL
Intervention: Standard care plus acupuncture
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 101
Study: 36479831

Group type: EXPERIMENTAL
Intervention: EHR-based coaching intervention
Number of subjects: 0
Study: 34429472

Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (3 sets for a total of 23 min)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Rest (control group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise
Number of subjects: 42
Study: 32501524

Group type: EXPERIMENTAL
Intervention: Dual-motor drill
Number of subjects: 5
Study: 34371859

Group type: EXPERIMENTAL
Intervention: Geriatric intervention with outreach team comprising a geriatrician and a dietician
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Geriatric intervention with outreach team
Number of subjects: 147
Study: 32658830

Group type: EXPERIMENTAL
Intervention: Acupuncture plus treatment as usual (TAU)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Progressive muscle relaxation (PMR) plus treatment as usual (TAU)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 57
Study: 34806261

Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 1156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1156
Study: 33394901

Group type: EXPERIMENTAL
Intervention: Traditional moderate-intensity continuous exercise program (TRAD), 30 min at 60%-80% of peak heart rate, 3 days/week for 12 weeks.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Stair climbing-based high-intensity interval training program (STAIR), 3 sets of 6 flights, 3 days/week for 12 weeks.
Number of subjects: 16
Study: 33524060

Group type: EXPERIMENTAL
Intervention: aboBoNT‐A (500 U in a 2‐mL injection volume)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: aboBoNT‐A
Number of subjects: 134
Study: 35507446

Group type: EXPERIMENTAL
Intervention: IVIg continuation
Number of subjects: 60

Group type: COMPARATOR
Intervention: IVIg withdrawal
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined MCIDs
Number of subjects: 60
Study: 32193249

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 11071
Study: 34763309

Group type: EXPERIMENTAL
Intervention: Time-restricted feeding (TRF) - limit 8 hours of eating time and fasting for 16 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional weight-loss method - unrestricted eating time
Number of subjects: 0
Study: 32186940

Group type: EXPERIMENTAL
Intervention: IVC injection 3 to 5 days before surgery (Group 1)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: IVC injection at the end of surgery (Group 2)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: IVC injection 3 to 5 days before and at the end of operation (Group 3)
Number of subjects: 98
Study: 35964868

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure for Primary Care (PE-PC) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 34353774

Group type: EXPERIMENTAL
Intervention: Rapid recovery protocol (RP) with local infiltration of levo‐bupivacaine and supervised ambulation 4‐6 hours after surgery.
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group with femoral nerve block and ambulation after drain removal.
Number of subjects: 175
Study: 32555681

Group type: COMPARATOR
Intervention: 2000 NGN (Model 1)
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: 3000 NGN (Model 1)
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: 1000 NGN plus reminder call (Model 2)
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: 3000 NGN plus reminder call (Model 2)
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Reminder calls plus CCTs
Number of subjects: 1088
Study: 33982219

Group type: EXPERIMENTAL
Intervention: TFES + biofeedback therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: TFES alone
Number of subjects: 40
Study: 34769561

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study: 32730049

Group type: EXPERIMENTAL
Intervention: Positive expectancy group with placebo neurofeedback
Number of subjects: 85

Group type: COMPARATOR
Intervention: Negative expectancy group with placebo neurofeedback
Number of subjects: 85
Study: 35537970

Group type: EXPERIMENTAL
Intervention: Thermal softening of double-lumen endobronchial tubes (DLTs) placed in 40°C 0.9% saline for 10 minutes
Number of subjects: 258

Group type: COMPARATOR
Intervention: Non-thermal softening group (control)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Thermal softening of double-lumen endobronchial tubes (DLTs)
Number of subjects: 258
Study: 36508996

Group type: EXPERIMENTAL
Intervention: Xanthohumol (Xn) at a daily dose of 4.5 mg/kg body weight for 7 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Xanthohumol (Xn)
Number of subjects: 50
Study: 34543081

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 32500934

Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii Hook F (TwHF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Systemic glucocorticoids
Number of subjects: 20
Study: 35939810

Group type: EXPERIMENTAL
Intervention: Ensovibep (600 mg intravenous)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Ensovibep
Number of subjects: 485
Study: 33772154

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX followed by CRT
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX alone
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX +/− CRT + surgery
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 330
Study: 32569258

Group type: EXPERIMENTAL
Intervention: Treatment for PID (current national treatment guidelines)
Number of subjects: 0
Study: 35858186

Group type: EXPERIMENTAL
Intervention: CHECC‐uP (community‐based health literacy intervention for cancer control)
Number of subjects: 123
Study: 33507248

Group type: EXPERIMENTAL
Intervention: Mifepristone (50 mg every 6 h for 9 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 34476450

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine combined with flurbiprofen axetil in addition to local anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Local anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (local anesthesia)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Experimental group (dexmedetomidine + flurbiprofen axetil)
Number of subjects: 40
Study: 34955488

Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Medical therapy without endovascular therapy
Number of subjects: 200
Study: 33711095

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee consumption
Number of subjects: 390435

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP)
Number of subjects: 390435

Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP)
Number of subjects: 390435

Group type: EXPERIMENTAL
Intervention: Resting Heart Rate
Number of subjects: 390435